BMS-Celgene merger chances improve with backing from proxy advisers
admin 29th March 2019 Uncategorised 0When it comes to Bristol-Myers Squibb’s Celgene buyout, two influential proxy advisory firms have spoken—and they’re in favor of the mammoth tie-up. That support deals a blow to investor rebels fighting the merger.
More: BMS-Celgene merger chances improve with backing from proxy advisers
Source: fierce